Market Research Report
Colorectal Cancer Drug Development Pipeline Review, 2017
|Published by||GlobalData||Product code||564938|
|Published||Content info||299 Pages
Delivery time: 1-2 business days
|Colorectal Cancer Drug Development Pipeline Review, 2017|
|Published: September 22, 2017||Content info: 299 Pages||
Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity. There are a total of 17 products in development for this indication, by 16 companies. The key company operating in this pipeline space is Advaxis, with two pipeline products in development.
Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources and personal or family history of polyps or colorectal cancer. There are a total of 10 products in development for this indication, developed by 10 companies. Key companies operating in this pipeline space include Abbvie and Advaxis.
Finally, colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. There are a total of 581 products in development for this indication, by 334 companies and 56 academic institutions. Key companies operating in this pipeline space include Novartis, Roche and Abbvie.
Across all three indications, viral proteins, immune checkpoint proteins, kinases and DNA-related proteins are the most common targets, reflecting heavily both the pathophysiology and current treatment landscape associated with these diseases.
The report, "Colorectal Cancer Drug Development Pipeline Review, 2017" provides an overview of the colorectal cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for anal, rectal and colorectal cancer, and features dormant and discontinued projects.